Risperidone News and Research

RSS
Antipsychotic medication reduces violent crime rates

Antipsychotic medication reduces violent crime rates

More antipsychotic medications prescribed to children and adolescents in Germany

More antipsychotic medications prescribed to children and adolescents in Germany

Study supports use of two drugs for treating children with aggression and disruptive behavior

Study supports use of two drugs for treating children with aggression and disruptive behavior

Forest Laboratories to acquire exclusive rights in the U.S. for Saphris sublingual tablets

Forest Laboratories to acquire exclusive rights in the U.S. for Saphris sublingual tablets

Janssen Pharmaceuticals to pay over $1.6 billion in drug misbranding case

Janssen Pharmaceuticals to pay over $1.6 billion in drug misbranding case

Phase III EINSTEIN trial program: XARELTO reduces risk of DVT and PE

Phase III EINSTEIN trial program: XARELTO reduces risk of DVT and PE

New behavioral therapy improves antidepressant treatment of OCD

New behavioral therapy improves antidepressant treatment of OCD

Antipsychotic drugs for children with behavioral problems may put at risk for type 2 diabetes

Antipsychotic drugs for children with behavioral problems may put at risk for type 2 diabetes

Antipsychotics seemed to normalize gene expression pattern in people with bipolar disorder: Study

Antipsychotics seemed to normalize gene expression pattern in people with bipolar disorder: Study

Off label atypical antipsychotic use lacks safety and effectiveness in patients over 40

Off label atypical antipsychotic use lacks safety and effectiveness in patients over 40

Janssen receives positive opinion from EMA CHMP for ZYTIGA to treat mCRPC

Janssen receives positive opinion from EMA CHMP for ZYTIGA to treat mCRPC

FDA accepts Sunovion’s two LATUDA sNDAs for review

FDA accepts Sunovion’s two LATUDA sNDAs for review

BioLineRx intends to conduct interim analysis of BL-1020 Phase II/III trial for schizophrenia

BioLineRx intends to conduct interim analysis of BL-1020 Phase II/III trial for schizophrenia

Antipsychotic drug quandary for Alzheimer’s patients

Antipsychotic drug quandary for Alzheimer’s patients

BioLineRx’s BL-1020 safe and effective in treating schizophrenia

BioLineRx’s BL-1020 safe and effective in treating schizophrenia

Treatment of Schizophrenia receives notice of intention to grant a European patent

Treatment of Schizophrenia receives notice of intention to grant a European patent

Newly diagnosed schizophrenia patients continue to use oral Abilify as first-line therapy

Newly diagnosed schizophrenia patients continue to use oral Abilify as first-line therapy

Sunovion announces results from LATUDA open-label study for schizophrenia

Sunovion announces results from LATUDA open-label study for schizophrenia

Positive results from Dainippon Sumitomo Pharma's LATUDA trials for bipolar I depression

Positive results from Dainippon Sumitomo Pharma's LATUDA trials for bipolar I depression

BioLineRx receives European patent for BL-1020 to treat schizophrenia

BioLineRx receives European patent for BL-1020 to treat schizophrenia